Pharmaceuticals
Merck Signs MoU with Ministry of Trade, Industry & Energy and Daejeon City for New Asia Pacific BioProcessing Production Center in South Korea
* MoU with Merck's Life Science business aimed at supporting the region's healthcare ecosystem * Proposed bioprocessing facility to be based in Daejeon City * Further collaboration aims to support emerging biotech companies and academic research DAEJEON CITY, South Korea, May 3, 2023 /PRNe...
2023-05-03 10:00
3384
Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients
SUZHOU, China, May 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the enrollment of ...
2023-05-03 08:00
3856
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment S...
2023-05-03 00:22
3347
Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis
* First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS). * Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803. HOUSTON, May 3, 2023 /PRNewswire/ -- Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic...
2023-05-03 00:07
2035
China Jo-Jo Drugstores Receives Hangzhou Municipal People's Government Quality Management Excellence Award
HANGZHOU, China, May 2, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that the Co...
2023-05-02 20:30
3324
Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne
HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ASC40 (Denifanstat), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, achieved primary and key secondary endpoints in Phase II clinical trial for acn...
2023-05-02 17:30
3572
First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide
MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged inCanada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for i...
2023-05-02 05:00
2298
I-MAB Filed 2022 Annual Report on Form 20-F
GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20...
2023-05-01 20:00
2146
Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease
TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an
Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel
MagicTouch
2023-05-01 18:30
2858
ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89 Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalT...
2023-05-01 08:58
2707
OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products
SHANGHAI, April 29, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE. Under the agreement, OBiO will provide holistic contract development and manufacturing services to CH...
2023-04-29 23:20
4330
IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study
SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants. IMG-004 is a potent, non-covalent, reversible, and brain permeable third-generation Br...
2023-04-28 17:00
1868
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability
* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. * The Company makes remarkable progress on environmental goals, achieving its water consumption intensity-reduction target in 2022, well a...
2023-04-28 14:43
2958
Brii Bio Publishes 2022 Environmental, Social and Governance Report
Brii Bio receives an "A" grade in the latest MSCI ESG Rating
DURHAM, N.C. and BEIJING, April 28, 2023 /PRNewswire/ -- Brii Biosciences
Limited
2023-04-28 09:00
3017
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio
- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development expertis...
2023-04-28 08:58
2141
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine
GERMANTOWN, Md. and GUANGZHOU, China, April 28, 2023 /PRNewswire/ -- RNAimmune, Inc.(the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the Uni...
2023-04-28 00:29
3115
Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation
- Aims to guide patients with rare and gastrointestinal diseases to appropriate medical care 〜Ubie will build on its achievements in the early detection of HAE and expand its collaboration with Takeda Pharmaceuticals to benefit patients in broader disease areas〜 NEW YORK, April 27, 2023 /PRNews...
2023-04-27 23:00
1886
Yuyu Pharma, Dry Eye Pipeline Mechanism of Action and Pre-clinical Results Published
SEOUL, South Korea, April 27, 2023 /PRNewswire/ -- At ARVO 2023, Yuyu Pharma unveiled the results of its mechanism of action and head-to- head studies for its dry eye treatment peptide (project name: YP-P10). ARVO is the world's largest ophthalmic society and held its annual meeting inNew Orleans...
2023-04-27 21:00
2084
Fosun Collaborates with Non-profit Organizations to Provide "Chinese Solutions" to Jointly Build a Malaria-free World
HONG KONG, April 27, 2023 /PRNewswire/ -- A song spreads throughout the world from the Premier League fields; a seminar explores how civilian orgnanizations can carry out charitable activities for long-term effect inAfrica; and a charity "relay race" starts at Guilin,China, where artesunate was d...
2023-04-27 19:36
3251
ASCO 2023 | Ascentage Pharma to Present Results from 4 Studies Highlighting Extended Therapeutic Potential of Lead Drug Candidates
SUZHOU, China, and ROCKVILLE, MD, April 27, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the c...
2023-04-27 17:44
1815
Week's Top Stories
Most Reposted
2024 Malaysia E-Commerce Product Selection Expo Attracts International Delegations
[Picked up by 311 media titles]
2024-12-02 12:06
ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 298 media titles]
2024-11-28 17:24AC Health makes critical HIV care more accessible to Filipinos with USAID support
[Picked up by 296 media titles]
2024-12-03 16:11
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 286 media titles]
2024-11-29 20:33
Hong Kong Airlines Resumes Vancouver Service Offering Twice-weekly direct flights from 18 January 2025
[Picked up by 283 media titles]
2024-12-02 20:01
Most Read
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
9327
China's spicy hotpot sets its sights on global market
2024-11-29 21:36
4004
CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
2024-11-30 09:00
3985